Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 276 to 300 of 872

TitleReference numberPublishedLast updated
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Upadacitinib for treating active ankylosing spondylitisTA829
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Brolucizumab for treating diabetic macular oedemaTA820
Avalglucosidase alfa for treating Pompe diseaseTA821
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815

Results per page

  1. 10
  2. 25
  3. 50
  4. All